Takashi Watanabe

Dr. Takashi Watanabe

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
TWTakashi Watanabe
Takashi Watanabe
TSTakahiro Saito
Takahiro Saito
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
EHEiji Hishinuma
Eiji Hishinuma
MKMasaki Kumondai
Masaki Kumondai
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

2 August 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
TWTakashi Watanabe
Takashi Watanabe
SKShota Kashiwagura
Shota Kashiwagura
RORyusuke Ouchi
Ryusuke Ouchi
KUKensuke Usui
Kensuke Usui
CSChikashi Shibata
Chikashi Shibata
KOKouji Okada
Kouji Okada
Background: Polypharmacy is an escalating public health concern across various healthcare settings worldwide. We aimed to comprehensively investigate postoperative complications after laparoscopic surgery for colorectal cancer and explore their association with polypharmacy. As laparoscopic surgery is widespread, clarifying the association between polypharmacy and postoperative complications is clinically important. Methods: We retrospectively surveyed the medical charts of adult inpatients who underwent laparoscopic surgery for colorectal cancer at Tohoku Medical and Pharmaceutical University Hospital between April 2019 and March 2023. Postoperative complications were determined using the Clavien–Dindo classification. We explored the factors related to postoperative complications and calculated the cut-off values for the number of medication ingredients. Results: Among the 236 patients, 32 (13.6%) developed postoperative complications. On multivariable logistic regression analysis, the number of regularly used medication ingredients (odds ratio = 1.160, 95% confidence interval 1.050–1.270, p = 0.002) was identified as a factor related to postoperative complications. The identified cut-off value for complications was 10 ingredients. Patients using 10 or more ingredients had approximately 3.5 times higher occurrence of postoperative complications than those using fewer than 10 ingredients (33.3% vs. 9.3%, p < 0.001, Fisher’s exact test). Conclusions: Our study comprehensively investigated postoperative complications and examined their association with polypharmacy. We found that the number of regularly used medication ingredients may be linked to complications following laparoscopic surgery for colorectal cancer. These findings have important implications for perioperative management and patient care, providing valuable insights that may influence clinical practices and enhance patient outcomes.


12 December 2022 in Cureus
Verified
Journal Article
Open access
RORyusuke Ouchi
Ryusuke Ouchi
SKShota Kashiwagura
Shota Kashiwagura
TWTakashi Watanabe
Takashi Watanabe
KUKensuke Usui
Kensuke Usui
JIJun Ito
Jun Ito
KOKouji Okada
Kouji Okada
We report two cases of pazopanib (PAZ)-induced liver injury in patients with metastatic renal cell carcinoma. The first patient was a 70-year-old female who was diagnosed with right renal cell carcinoma and showed tumor embolism in the inferior vena cava. PAZ was started but discontinued after about one month due to a grade four liver injury. The second patient was a 60-year-old male who was diagnosed with left renal cell carcinoma and suspected multiple lung metastases. PAZ was started following a laparoscopic left radical nephrectomy but was stopped after about a month due to a grade three liver injury. We analyzed the plasma PAZ concentrations for treatment evaluation. High plasma PAZ concentrations were observed in both patients after PAZ treatment began. Severe liver injury after PAZ administration may be associated with high plasma PAZ concentrations; hence, we should reduce PAZ dosage early. We also recommend monitoring plasma PAZ concentrations, if possible, so that physicians can either reduce the dosage or discontinue treatment to avoid further liver damage.

29 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YNYosuke Nishikawa
Yosuke Nishikawa
HSHiroyuki Suzuki
Hiroyuki Suzuki
RORyusuke Ouchi
Ryusuke Ouchi
TKTaisuke Konno
Taisuke Konno
KUKensuke Usui
Kensuke Usui
YMYuriko Murai
Yuriko Murai
Background/Objectives: Risperidone oral solution (RIS-OS) is an easy-to-administer treatment for schizophrenia designed to improve medication adherence and rapid onset of effect. Mixing RIS-OS with beverages such as black tea is prohibited due to reduced RIS concentrations observed in vitro, despite the absence of pharmacokinetic data. In this study, we evaluated the pharmacokinetics of RIS and its active metabolite 9-OH-RIS in rats following oral administration with black tea. Methods: Male Wistar rats received RIS-OS intravenously or orally as a water or Dimbula black tea mixture; serial tail-vein blood samples were collected as dried blood spots, RIS and 9-OH-RIS were quantified using HPLC/ESI-MS/MS, and pharmacokinetic parameters were calculated and compared using Welch’s t-test. Results: Compared with the water mixture, the black tea mixture significantly reduced RIS Cmax, while Tmax and AUC remained unchanged. Furthermore, AUMC and MRT were significantly higher. The results were similar for 9-OH-RIS. Despite reduced RIS content in vitro, no difference in absolute bioavailability was observed in vivo. Although only one black tea variety was tested, evaluating additional varieties may help identify the components responsible for reducing RIS content. Conclusions: Mixing RIS-OS with black tea may delay absorption without reducing overall exposure, providing evidence that may contribute to safer guidance regarding beverage coadministration.

27 June 2026 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
TWTakashi Watanabe
Takashi Watanabe
NSNaoto Suzuki
Naoto Suzuki
MYMasahito Yamauchi
Masahito Yamauchi
NINaoki Iinuma
Naoki Iinuma
MSMakoto Shiozawa
Makoto Shiozawa
KOKouji Okada
Kouji Okada
Background: To investigate immune-related adverse events (irAEs) in patients with non-small cell lung cancer receiving immune checkpoint inhibitor (ICI) therapy, and to identify clinical factors associated with irAE onset, thus supporting safer immunotherapy through effective monitoring. Methods: This retrospective cohort study was conducted at Tohoku Medical and Pharmaceutical University Hospital over approximately 5 years. Hospitalized patients with non-small cell lung cancer who received immune checkpoint inhibitors for the first time were included. Physicians and pharmacists evaluated the occurrence, severity, and timing of irAEs. Cox proportional hazards regression and Fine–Gray competing risk analyses were performed to identify factors associated with irAE development. Results: Among the 203 enrolled patients, 92 (45.3%) experienced irAEs, totaling 110 events. The most common irAE was interstitial lung disease (23 cases, 20.9%), followed by thyroid dysfunction (20 cases, 18.2%). In multivariable Cox regression analysis, comorbid heart failure was significantly associated with a reduced risk of irAE development (hazard ratio, 0.299; 95% confidence interval [CI], 0.135–0.663; p = 0.003), and this association remained significant in the Fine–Gray competing risk model (subdistribution hazard ratio, 0.335; 95% CI, 0.147–0.766; p = 0.009). To address potential multicollinearity, an alternative model incorporating regular use of renin–angiotensin–aldosterone system inhibitors in place of comorbid heart failure also demonstrated a significant association with irAE incidence. Conclusions: In this Japanese non-small cell lung cancer cohort, comorbid heart failure emerged as a potential modifier of irAE incidence, suggesting that baseline cardiac conditions may influence susceptibility to immune‑related toxicity. These findings underscore the importance of incorporating comorbidity profiles into individualized irAE monitoring strategies during cancer immunotherapy.